News | August 18, 2008

Atritech Files Pre-Market Approval Application for WATCHMAN LAA Closure Technology

August 18, 2008 - Atritech Inc. today said it filed its pre-market approval application (PMA) with the FDA for its WATCHMAN Left Atrial Appendage (LAA) Closure Technology, which contains the results of the PROTECT AF Clinical Trial which began enrollment in early 2005.

PROTECT AF evaluated the WATCHMAN versus the current standard of care, warfarin, in patients with non-valvular atrial fibrillation at risk of stroke. The trial enrolled 800 patients and was conducted in 60 centers across the U.S. and Europe.

The first patient has been enrolled into the Continued Access Registry at Washington Hospital Center under the direction of Prof. Horst Sievert and Dr. Ron Waksman.

“The PROTECT AF Trial results are highly anticipated to all those who manage patients with atrial fibrillation, the most common sustained cardiac arrhythmia,” said Vivek Reddy, M.D., director of cardiac electrophysiology, University of Miami. “We trust the data will support the approval of the WATCHMAN technology, providing clinicians with an additional tool to manage patients with atrial fibrillation.”

Atritech’s WATCHMAN LAA Closure Technology is designed to keep harmful sized blood clots from entering a patient's blood stream, potentially causing a stroke. Patients with atrial fibrillation (a heart condition that causes the upper chambers of the heart to beat too rapidly) are at a greater risk of having a stroke. Typically these patients require blood-thinning medications to prevent these clots from forming in the heart. Current medical therapy requires frequent monitoring and has diet and other drug interactions causing many patients to stop taking them. The WATCHMAN device may be an alternative for patients with atrial fibrillation who may not want to take blood-thinning medications for life, the company said.

Last year, Atritech announced the acquisition of intellectual property from ev3 Inc. (EVVV) covering left atrial appendage closure devices.

For more information: www.atritech.net

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init